Clinical trials: Headache, Migraine
Acute Migraine
Chordate System S020 Acute Migraine Clinical Investigation
The main purpose of the study is to evaluate the impact of treatment with the Chordate System S020 (medical device) on acute migraine headache pain.
- Trial name
- Amici (NCT02185703)
- Testing
- Chordate System S020 in treatment mode
- Where
- 9 sites in Germany
- Volunteers
- 51 people
- Sponsor
- Chordate Medical
Chronic Migraine
Non-Invasive Neurostimulation for the Prevention of Chronic Migraine
The purpose of this multi-center, prospective, double-blind, randomized, sham-controlled pilot study is to study feasibility and collect preliminary clinical data related to the safety and clinical benefits of daily use of…
- Trial name
- NCT01667250
- Testing
- GammaCore Active Device
- Where
- 6 sites in United States
- Volunteers
- 59 people
- Sponsor
- ElectroCore INC
Migraine
Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults
The purpose of this is study is to compare the efficacy of BHV-3000 (rimegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
- Trial name
- NCT03732638
- Testing
- Rimegepant
- Where
- 93 sites in United States
- Volunteers
- 1,590 people
- Sponsor
- Pfizer
Chronic Migraine, Episodic Migraine
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Conditions
- Chronic Migraine, Episodic Migraine, Migraine
- Trial name
- Atogepant PMSS (NCT06603558)
- Testing
- Atogepant
- Where
- 36 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- AbbVie
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and…
- Trial name
- NCT02848326
- Testing
- Atogepant
- Where
- 75 sites in United States
- Volunteers
- 834 people
- Sponsor
- Allergan
Migraine Headache
A Study in Migraine Prevention
The primary objective of this study is to measure the change in frequency of migraine attacks per 28 days in migraine patients being treated orally with LY2300559 for 12 weeks.
- Trial name
- NCT01184508
- Testing
- LY2300559
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 87 people
- Sponsor
- Eli Lilly and Company
Migraine, Migraine With Aura
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
Study STS101-007 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute…
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- SUMMIT (NCT04940390)
- Testing
- Dihydroergotamine
- Where
- 127 sites in United States
- Volunteers
- 1,591 people
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Migraine
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
The primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.
- Trial name
- EMBRACE (NCT04252742)
- Testing
- Erenumab
- Where
- 91 sites in United States, Bulgaria and 7 more
- Volunteers
- 512 people
- Sponsor
- Amgen
Migraine Disorders
An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention
This is a prospective, multi-center, unblinded study in patients with migraine (≥ 8 MMDs(monthly migraine days)/month) requiring preventive treatment.
- Trial name
- NCT06154070
- Testing
- DaxibotulinumtoxinA
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Ki Health Partners. LLC
Migraine Disorders, Refractory Migraine
EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization
This single-site, open-label pilot study evaluates the safety, feasibility, and potential durability of the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy targeting meningeal…
- Conditions
- Migraine Disorders, Refractory Migraine, Chronic Migraine
- Trial name
- EMBRACE (NCT07313800)
- Testing
- TEMMA Endovascular Treatment
- Where
- United States
- Sponsor
- Cortex Neurovascular
Migraine
Safety, Efficacy and Pharmacokinetics of ALD403
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of a single dose of ALD403 in the prevention of migraine headache in frequent episodic migraineurs for 24 weeks.
- Trial name
- NCT01772524
- Testing
- ALD403
- Where
- 26 sites in United States
- Volunteers
- 163 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Migraine
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine
To evaluate the efficacy and safety of subcutaneous (SC) administration of TEV-48125 [monthly TEV-48125 225 mg (loading dose only: 675 mg) and TEV-48125 675 mg once over a period of 3 months] compared with placebo for preventive…
- Trial name
- NCT03303079
- Testing
- TEV-48125
- Where
- Japan
- Volunteers
- 571 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Migraine, Acute Treatment of Migraine
Nerivio Efficacy by Time of Treatment Onset
This is a Post-marketing study investigating the impact of treatment time onset with Nerivio on the efficacy of Remote Electrical Neuromodulation (REN) for the acute treatment of migraine.
- Trial name
- NCT06976723
- Testing
- Nerivio
- Where
- United States
- Volunteers
- 55,261 people
- Sponsor
- Theranica
Migraine Headache
Treatment of Multiple Attacks of Acute Migraine (0462-025)
A study to evaluate rizatriptan for the treatment of multiple attacks of acute migraine compared to placebo.
- Trial name
- NCT00899379
- Testing
- rizatriptan benzoate
- Volunteers
- 473 people
- Sponsor
- Organon and Co
Migraine
Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds
Study Objectives: 1. The primary objective is to characterize the pharmacokinetics of a single oral administration of 50 mg Cambia in pediatric subjects, ages 12-17 years with a diagnosis of episodic migraine with or without…
- Trial name
- NCT02287376
- Testing
- Diclofenac Potassium for Oral Solution
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Depomed
Migraine
Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED)
This study will evaluate the comparative bioavailability of three capsule formulations of MK-0974.
- Trial name
- NCT01209741
- Testing
- telcagepant potassium, MK-0974 5Mo5C, MK-0974 12Mo5C
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
Real World Data Analysis: Impact of High-Frequency REN Treatments As Migraine Preventive Therapy in Adolescence
This is a post-marketing study investigating the safety and efficacy of the REN device (Nerivio by Theranica, ISRAEL) in adolescents with migraine.
- Trial name
- NCT05769322
- Testing
- Nerivio
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Theranica
Migraine
Study of Wireless Nerve Stimulation in the Treatment of Chronic Migraine
The purpose of this study is to illustrate the safety and effectiveness of the StimRelieve Halo Nerve Stimulator System in the treatment of chronic migraine.
- Trial name
- NCT02725554
- Testing
- StimRelieve Halo System
- Sponsor
- Curonix LLC
Migraine
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
The purpose of this study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks. Rimegepant is a tablet that disintegrates when you put it on or under your tongue.
- Trial name
- NCT06616194
- Testing
- Rimegepant
- Where
- 102 sites in United States, Canada and 10 more
- Volunteers
- 636 people
- Sponsor
- Pfizer
Acute Migraine
Safety and Efficacy of Nerivio™ for the Acute Treatment of Migraine in Adolescents
Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine.
- Trial name
- NCT04089761
- Testing
- Nerivio
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Theranica